Milrinon Hikma (Milrinone)

• Milrinone is used in the management of acute cardiac conditions that require inotropic support.
• Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion, helping stabilize patients.
• Cardiogenic shock: provides rapid hemodynamic stabilization by increasing contractility and lowering systemic vascular resistance.
• Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to support circulation during the postoperative period.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to accumulation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while also causing vasodilation through reduced calcium‑mediated smooth‑muscle contraction, thereby decreasing afterload.

Milrinone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypotension: reduced blood pressure, especially with rapid infusion.
• Arrhythmias: premature ventricular contractions or tachyarrhythmias.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: transient warmth and redness of the skin.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: profound drop in blood pressure requiring intervention.
• Ventricular arrhythmias: life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Thrombocytopenia: significant drop in platelet count.
• Anaphylactic reactions: rare but potentially fatal allergic response.
• Elevated liver enzymes: indication of hepatic stress.

• Milrinon Hikma requires careful clinical monitoring and adherence to safety guidelines.
• Renal impairment: adjust monitoring and dosage as needed.
• Hypotension: monitor blood pressure closely during infusion.
• Arrhythmias: avoid in patients with pre‑existing ventricular arrhythmias.
• Concomitant vasodilators: use with caution due to additive hypotensive effect.
• Pregnancy: safety not established; use only if benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinon Hikma can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid)

• Concurrent use with other phosphodiesterase‑3 inhibitors: risk of excessive vasodilation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma levels.
• Potent vasodilators (e.g., nitroprusside): can cause severe hypotension.

Moderate Interactions (Monitor Closely)

• Beta‑adrenergic agonists: additive inotropic effect may precipitate tachyarrhythmias.
• Diuretics: electrolyte shifts may augment arrhythmic risk.
• Anticoagulants: potential for increased bleeding if platelet counts fall.